Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms.
10.19746/j.cnki.issn.1009-2137.2021.05.026
- Author:
Jiao YAN
1
;
Ya-Wen DING
2
;
Peng-Yu WANG
2
;
Yi-Peng WU
2
;
Hui-Chao ZHANG
3
;
Li-Hong LIU
4
Author Information
1. Department of Hematology,The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
2. Cinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
3. Cinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China. E-mail: zhanghuichao050108@163.com.
4. Department of Hematology,The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China. E-mail: 13831177920@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Female;
Fusion Proteins, bcr-abl/genetics*;
Humans;
Janus Kinase 2/genetics*;
Male;
Middle Aged;
Myeloproliferative Disorders/genetics*;
Polycythemia Vera;
Thrombocythemia, Essential;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(5):1540-1547
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the disease types, clinical manifestations, efficacy and outcome of JAK2 V617F and BCR-ABL double-mutant myeloproliferative neoplasms (MPN), and provide a reference for the diagnosis, treatment and prognosis of MPN.
METHODS:The clinical characteristics, diagnosis, therapeutic efficacy and outcome of JAK2 V617F and BCR-ABL double-mutant MPN were analyzed comprehensitively by combining a clinical case diagnosed and treated in our hospital with literature cases from CNKI and PubMed databases.
RESULTS:A total of 38 related literatures were retrieved from the two databases by searching "JAK2 V617F" and "BCR-ABL" as key words from 1990 to 2019, and 59 cases were involved. Among all the 60 cases, 41 were males (68.3%) with a median age of 61 (32-77) years old, while 19 were females (31.7%) with a median age of 58 (21-82) years old. The BCR-ABL fusion gene and JAK2 V617F mutation were found simultaneously in 21 cases (35%), 19 cases (31.7%) with JAK2 V617F mutation were found during the treatment of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Ph
CONCLUSION:As cases of BCR-ABL and JAK2 V617F double-mutant MPN are reported, simultaneous detection of JAK2 V617F mutation and BCR-ABL fusion gene in MPN patients is necessary to avoid misdiagnosis and missed diagnosis.
